Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat

Q3 · MEDICINE

Article

Author: THOMSON, A W ; SEWELL, A F ; STEWART, L S

SUMMARYRats received a single high dose of cyclophosphamide (Cy) (150 mg/kg). followed 48 h later (on day 0) by immunization with a T cell-dependent soluble antigen, ovalbumin in Freund's complete adjuvant (FCA). The effect of this treatment on lymphoid cell subpopulalions in the spleen, natural killer (NK) cell and interieukin-2 (IL-2) induced lymphokine-activated killer (LAK) cell activity was examined. Cy (with and without ovalbumin) caused a large relative increase (by day 14) in splenic OX 8+, OX 19-cells with NK morphology. A marked relative increase in fresh NK cell activity was noted after Cy+ovalbumin, but not consistently after Cy alone. Elevated NK activity was Cy dose- and time-dependent, was evident within 7 days post Cy/ovalbumin and persisted for at least 28 days. Pooled splente mononuclear cells (MNC), obtained 14 days after Cy/ovulbumin, lost all cytolytic activity against YAC-I cells when cultured in the absence of human recombinant IL-2 (rIL-2). In contrast, similarly maintained cells from normal rats displayed NK activity higher than normal‘fresh’levels. Upon culture in medium containing 500 U/ml rIL-2, however,‘augmented’NK. activity was equivalent, on a per-cell basis, in both normal and Cy/ovaibumin-pretreuted groups. LAK activity generated in vitro (i.e. against NK.-resistant target cells) was significantly lower in the latter group, and the overall yield of cells was reduced. By day 21 after Cy/ovaibumin, augmented NK activity was significantly greater lhan controls, on a per-cell and total culture yield basis. Moreover, LAK activity was now similar between groups. It is concluded that the chemotherapy/immunization protocol which we have used can greatly enhance NK activity in vitro and that these cells are responsive to induction of LAK activity by IL-2 in ritro.

28 Jun 2008·Clinical and Experimental ImmunologyQ3 · MEDICINE

Macrophage depletion decreases IgG anti-DNA in cultures from (NZB · NZW)F1 spleen cells by eliminating the main source of IL-6

Q3 · MEDICINE

Article

Author: FERNÁNDEZ, C ; MÖLLER, G ; ALARCÓN-RIQUELME, M E

SUMMARYWe have studied ihe rote of macrophages in the produclion of IgG anli-DNA autoanlibodies by (NZB × NZW)F1 tnice(B/W). One of the main features of the syslemic lupus cryibematosus(SLE)-like disease that aftects these mice, h ihe presence of circuialing IgG autoantibodies and immune complexes, which lead lo renal failure and death by the age of 8–9 months. IgG autoantibodies are produced without in vitro siimulallon by lolal spleen eells from these miee when they reach tbe age of 6 monlhs. We have demonstrated ihat IL-6 increases ihe production of IgG autoantibodies in cultures of splenic purified B cells from the old B/W miee. The aim of this study was to show the involvement of macrophages in the production of IL-6 and consequently in the produclion of IgG anti-DNA antibodies in ritro. We show thai elimination of the macrophages by different treatments led to reduction of the content of IL-6 in ihe supernalants as well as of IgG anti-DNA autoantibodies. Addition of fresh, splenic or peritoneal macrophages restored the produclion of autoantibodies in macrophage-depleted cultures from old B/W miee. There were no ditferences in the capacity of IL-6 produelion between macrophages from old or young B/W miee. but an imporiani difference was observed between peritoneal and splenic maerophages, where the former produced mueh higher levels ol IL-6, and eonsequently were more potent inducers of IgG autoantibodies. The present results reinforee Ihe role of macrophages and lL-6 in Ihe production of IgG anti-DNA autoantibodies in B/W mice. The implieations of these results in the pathogenesis of the disease are discussed.

01 Oct 2004·Current MicrobiologyQ4 · BIOLOGY

Structure?Activity Relationships for Three Macrolide Antibiotics in Haemophilus influenzae

Q4 · BIOLOGY

Article

Author: Jessica Eller ; Susan Mabe ; W. Scott Champney

A prior study examining differences in the activities of erythromycin and azithromycin on cellular functions in the Gram-negative pathogen, Haemophilus influenzae, revealed a marked difference in their inhibitory activities. The study revealed that protein synthesis and 50S ribosomal subunit assembly were equal targets for inhibition by azithromycin while erythromycin was a preferential inhibitor of translation. This contrast in inhibitory activities stimulated a comparative analysis of three additional antibiotics: clarithromycin, flurithromycin and roxithromycin. Each compound was tested over a concentration range for inhibitory effects on cellular processes. Clarithromycin was the most effective inhibitor of protein synthesis with an IC(50) of 5.6 microg/mL, followed by flurithromycin at 6 microg/mL, and roxithromycin at 9 microg/mL. IC(50) values for antibiotic effects on viable cell counts and growth rates were similar to those obtained for protein synthesis. Flurithromycin had the strongest effect on 50S ribosomal subunit formation with an IC(50) of 8 microg/mL, followed by clarithromycin and roxithromycin, at 9.0 microg/mL and 12.5 microg/mL respectively. 30S ribosomal subunit formation in cells treated with flurithromycin and roxithromycin was also reduced to some extent. Pulse-and-chase labeling kinetics examining subunit assembly rates verified the slower synthesis rate of the subunits in the presence of each macrolide. The results are discussed in terms of structural differences of these macrolides and their differential inhibitory effects on both cellular targets.

100 Deals associated with Flurithromycin Ethyl Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Flurithromycin Ethyl Succinate	J01FA14	DB13338

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mouth Diseases	IT	-	22 Apr 1998
Respiratory Tract Infections	IT	-	19 Apr 1998
Bacterial Infections	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis